Cantor Fitzgerald Reiterates Overweight on Lipocine, Maintains $33 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on Lipocine (NASDAQ:LPCN) and maintained a $33 price target.
July 27, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Lipocine and maintained a $33 price target, which could positively impact the stock.
The reiteration of an Overweight rating by Cantor Fitzgerald, along with the maintenance of a $33 price target, indicates a positive outlook for Lipocine. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100